United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
487.61
-2.63 (-0.54%)
Sep 4, 2026, 4:00 PM EDT - Market closed
United Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,155 | 3,183 | 2,877 | 2,328 | 1,936 | 1,686 |
| 3,155 | 3,183 | 2,877 | 2,328 | 1,936 | 1,686 | |
Revenue Growth | 2.49% | 10.61% | 23.63% | 20.20% | 14.88% | 13.63% |
Cost of Revenue | 437.2 | 384.4 | 309.7 | 257.5 | 151.6 | 122.5 |
Gross Profit | 2,717 | 2,798 | 2,568 | 2,070 | 1,785 | 1,563 |
Selling, General & Admin | 761.1 | 731.2 | 635.2 | 473.6 | 472.8 | 466.1 |
Research & Development | 551.5 | 550 | 481 | 408 | 322.9 | 410 |
Operating Expenses | 1,313 | 1,281 | 1,116 | 881.6 | 795.7 | 876.1 |
Operating Income | 1,405 | 1,517 | 1,452 | 1,188 | 989 | 686.9 |
Interest Expense | -12 | -19.5 | -42.9 | -59.3 | -32.4 | -18.6 |
Interest & Investment Income | 162.9 | 192 | 199.1 | 162.7 | 45.2 | 16.7 |
Other Non Operating Income (Expenses) | 16.3 | 6 | -6.6 | -17.5 | -38.3 | 43.8 |
EBT Excluding Unusual Items | 1,572 | 1,696 | 1,601 | 1,274 | 963.5 | 728.8 |
Gain (Loss) on Sale of Investments | 4.1 | 43 | 9 | - | -1.7 | -2.3 |
Asset Writedown | - | -21.7 | - | - | -11.2 | -132.6 |
Legal Settlements | -3 | -3 | -71.1 | - | - | - |
Pretax Income | 1,573 | 1,714 | 1,539 | 1,274 | 950.6 | 593.9 |
Income Tax Expense | 262.1 | 379.2 | 343.9 | 289.5 | 223.3 | 118.1 |
Net Income | 1,311 | 1,335 | 1,195 | 984.8 | 727.3 | 475.8 |
Net Income to Common | 1,311 | 1,335 | 1,195 | 984.8 | 727.3 | 475.8 |
Net Income Growth | 5.54% | 11.68% | 21.36% | 35.41% | 52.86% | -7.58% |
Shares Outstanding (Basic) | 43 | 44 | 45 | 47 | 46 | 45 |
Shares Outstanding (Diluted) | 47 | 48 | 49 | 50 | 49 | 47 |
Shares Change | -3.20% | -1.24% | -2.41% | 2.47% | 2.54% | 6.05% |
EPS (Basic) | 30.27 | 30.13 | 26.44 | 21.04 | 15.98 | 10.60 |
EPS (Diluted) | 27.95 | 27.86 | 24.64 | 19.81 | 15.00 | 10.06 |
EPS Growth | 9.04% | 13.07% | 24.38% | 32.07% | 49.10% | -12.83% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1,093 | 1,041 | 1,081 | 747.6 | 663.7 | 477.4 |
Free Cash Flow Per Share | 23.30 | 21.73 | 22.28 | 15.04 | 13.69 | 10.09 |
Gross Margin | 86.14% | 87.92% | 89.24% | 88.94% | 92.17% | 92.73% |
Operating Margin | 44.53% | 47.67% | 50.44% | 51.06% | 51.08% | 40.75% |
Profit Margin | 41.56% | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% |
Free Cash Flow Margin | 34.65% | 32.70% | 37.55% | 32.12% | 34.28% | 28.32% |
EBITDA | 1,496 | 1,603 | 1,524 | 1,242 | 1,040 | 736.8 |
EBITDA Margin | 47.43% | 50.36% | 52.96% | 53.34% | 53.73% | 43.71% |
D&A For EBITDA | 91.5 | 85.6 | 72.5 | 53.2 | 51.3 | 49.9 |
EBIT | 1,405 | 1,517 | 1,452 | 1,188 | 989 | 686.9 |
EBIT Margin | 44.53% | 47.67% | 50.44% | 51.06% | 51.08% | 40.75% |
Effective Tax Rate | 16.66% | 22.13% | 22.35% | 22.72% | 23.49% | 19.89% |